Article Text

other Versions

PDF
Infliximab improves vascular stiffness in patients with rheumatoid arthritis
  1. Melinda Wong (wongbell{at}optusnet.com.au)
  1. Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
    1. Stephen Philip Oakley (stephen.oakley{at}hnehealth.nsw.gov.au)
    1. Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
      1. Laurel Young (laurel.young{at}rbbh-tr.nhs.uk)
      1. Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
        1. BenYu Jiang (ben_yu.jiang{at}kcl.ac.uk)
        1. St. Thomas’ Hospital and King’s College, London, United Kingdom
          1. Anthony S Wierzbicki (anthony.wierzbicki{at}kcl.ac.uk)
          1. St. Thomas’ Hospital and King’s College, London, United Kingdom
            1. Gabriel Panayi (gabriel.panayi{at}kcl.ac.uk)
            1. King’s College, London, United Kingdom
              1. Phil Chowienczyk (phil.chowienczyk{at}kcl.ac.uk)
              1. St. Thomas’ Hospital and King’s College, London, United Kingdom
                1. Bruce W Kirkham (brucekirkham{at}btinternet.com)
                1. Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom

                  Abstract

                  Objectives: Patients with rheumatoid arthritis (RA) have increased cardiovascular mortality. Tumour necrosis factor α (TNFα)-blocking therapy has been shown to reduce RA disease activity measures and joint damage progression. Some observational studies suggest TNFα blockade reduces mortality and incidence of first cardiovascular events. The mechanisms contributing to these outcomes are unclear. This study assessed the effects of infliximab treatment on vascular stiffness and structure in patients with RA.

                  Methods: This post-hoc analysis of longitudinal data from a randomised placebo-controlled study evaluated the effect of infliximab upon vascular assessments. 26 patients received intravenous infliximab (3mg/kg) at weeks 0, 2, 6 and every 8 weeks thereafter to week 54. Patients were followed up to 56-weeks of infliximab therapy with assessments of RA disease activity, cardiovascular risk factors, vascular stiffness (pulse wave velocity [PWV]), carotid intima-media thickness (CIMT) and carotid artery plaque (CAP). Univariate analyses of changes over time by repeated measures analysis of variance (RM ANOVA) were followed by multivariate time-series regression analysis (TSRA) if changes were seen.

                  Results: PWV was significantly lower (better) after 56 weeks of treatment with infliximab (ANOVA p<0.01, TSRA p<0.01). However CIMT (ANOVA p=0.50) and CAP (χ2=4.13, p=0.88) did not change over the study period. Multiple cardiovascular risk measures did not change with therapy and did not correlate with changes in measures of vascular structure.

                  Conclusions: Arterial stiffness improves with infliximab treatment in RA. This change may help explain the improved cardiovascular disease survival in RA patients receiving TNFα-blocking therapy.

                  Statistics from Altmetric.com

                  Request permissions

                  If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.